Relief And Acer Therapeutics Secures Orphan Drug Designation From European Union For Metabolic Disorder Candidate
The European Commission has granted orphan medicinal product designation in the EU to Relief Therapeutics and Acer Therapeutics’ (NASDAQ: ACER) lead asset ACER-001 (sodium phenylbutyrate) for the potential treatment of patients with Maple Syrup Urine Disease (MSUD).
